Identification
- Summary
Ammonia N-13 is a radioactive diagnostic agent used in PET (positron emission tomography) scans.
- Brand Names
- Ammonia N 13
- Generic Name
- Ammonia N-13
- DrugBank Accession Number
- DB09326
- Background
Ammonia N 13 Injection, USP is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. The active ingredient, [13N] ammonia, has the molecular formula of 13NH3 with a molecular weight of 16.02. Ammonia N 13 Injection, USP is used for imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Ammonia N-13 (DB09326)
- Weight
- Average: 16.03
Monoisotopic: 16.029213681 - Chemical Formula
- H3N
- Synonyms
- (13N)Ammonia
- Ammonia N 13
Pharmacology
- Indication
For diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Diagnostic agent Coronary artery disease •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Following intravenous injection, ammonia N 13 enters the myocardium through the coronary arteries. The PET technique measures myocardial blood flow based on the assumption of a three-compartmental disposition of intravenous ammonia N 13 in the myocardium. In this model, the value of the rate constant, which represents the delivery of blood to myocardium, and the fraction of ammonia N 13 extracted into the myocardial cells, is a measure of myocardial blood flow. Optimal PET imaging of the myocardium is generally achieved between 10 to 20 minutes after administration.
- Mechanism of action
Ammonia N 13 Injection is a radiolabeled analog of ammonia that is distributed to all organs of the body after intravenous administration. It is extracted from the blood in the coronary capillaries into the myocardial cells where it is metabolized to glutamine N 13 and retained in the cells. The presence of ammonia N 13 and glutamine N 13 in the myocardium allows for PET imaging of the myocardium.
- Absorption
Following intravenous injection, 13N-ammonia is cleared rapidly from the blood with a biologic half-life of about 2.84 minutes (effective half-life of about 2.2 minutes). In the myocardium, its biologic half-life has been estimated to be less than 2 minutes (effective half-life less than 1.67 minutes).
- Volume of distribution
0.8 ml/g.
- Protein binding
has not been studied.
- Metabolism
Ammonia N 13 undergoes a five-enzyme step metabolism in the liver to yield urea N 13 (the main circulating metabolite). It is also metabolized to glutamine N 13 (the main metabolite in tissues) by glutamine synthesis in the skeletal muscles, liver, brain, myocardium, and other organs. Other metabolites of ammonia N 13 include small amounts of N 13 amino acid anions (acidic amino acids) in the forms of glutamate N 13 or aspartate N 13.
- Route of elimination
Urinary excretion mainly as urea N 13.
- Half-life
2.84 minutes.
- Clearance
The radioactivity cleared from the blood very rapidly with 85% clearance in the first minute.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Data not available.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ammonia N 13 Injection 37.5 mCi/1mL Intravenous THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2007-08-23 Not applicable US 
AmmoniaN 13 N 13 Injection 37.5 mCi/1mL Intravenous Children's Hospital Of Michigan 2012-01-30 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ammonia N 13 Injection 37.5 mCi/1mL Intravenous NukeMed, Inc. dba SpectronRx 2015-04-24 Not applicable US Ammonia N 13 Injection 37.5 mCi/1mL Intravenous University of Alabama at Birmingham 2018-10-01 Not applicable US Ammonia N 13 Injection, solution 37.5 mCi/1mL Intravenous Biomedical Research Foundation Of Northwest Louisiana 2015-05-14 Not applicable US Ammonia N 13 Injection 37.5 mCi/1mL Intravenous University of Wisconsin System 2020-09-09 Not applicable US Ammonia N 13 Injection 37.5 mCi/1mL Intravenous Decatur Memorial Hospital 2019-11-06 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AmmoniaN 13 N 13 Ammonia N-13 (37.5 mCi/1mL) Injection Intravenous Children's Hospital Of Michigan 2012-01-30 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as homogeneous other non-metal compounds. These are inorganic non-metallic compounds in which the largest atom belongs to the class of 'other non-metals'.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous non-metal compounds
- Class
- Homogeneous other non-metal compounds
- Sub Class
- Not Available
- Direct Parent
- Homogeneous other non-metal compounds
- Alternative Parents
- Not Available
- Substituents
- Homogeneous other non metal
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9OQO0E343Z
- CAS number
- 34819-78-8
- InChI Key
- QGZKDVFQNNGYKY-BJUDXGSMSA-N
- InChI
- InChI=1S/H3N/h1H3/i1-1
- IUPAC Name
- (¹³N)ammonia
- SMILES
- [13NH3]
References
- General References
- External Links
- PubChem Compound
- 119432
- PubChem Substance
- 310265208
- ChemSpider
- 106665
- 1305558
- ChEBI
- 135980
- ChEMBL
- CHEMBL1201189
- Wikipedia
- Nitrogen-13
- FDA label
- Download (159 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count Not Available Recruiting Not Available Arterial Occlusive Diseases / Arteriosclerosis / Cardiovascular Disease (CVD) / Coronary Artery Disease (CAD) / Coronary Heart Disease (CHD) / Myocardial Ischemia / Vascular Diseases 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intravenous 260 mCi/1mL Injection, solution Intravenous 37.5 mCi/1mL Injection, solution Intravenous 260 mCi/1mL Injection Intravenous 37.5 mCi/1mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.98 Chemaxon pKa (Strongest Basic) 8.86 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 13.59 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 15.51 m3·mol-1 Chemaxon Polarizability 1.99 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-014i-9000000000-92ab2d6b6fd9cfb23ac7 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-9000000000-4d3180e05bafd704562f Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-9000000000-e1d016c3d6effe2294d2 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-9000000000-4d3180e05bafd704562f Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-9000000000-e1d016c3d6effe2294d2 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-9000000000-4d3180e05bafd704562f Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-9000000000-e1d016c3d6effe2294d2 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 110.90444 predictedDeepCCS 1.0 (2019) [M+H]+ 112.685356 predictedDeepCCS 1.0 (2019) [M+Na]+ 119.57529 predictedDeepCCS 1.0 (2019)
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Arginine binding
- Specific Function
- Plays a role in the regulation of ureagenesis by producing the essential cofactor N-acetylglutamate (NAG), thus modulating carbamoylphosphate synthase I (CPSI) activity.
- Gene Name
- NAGS
- Uniprot ID
- Q8N159
- Uniprot Name
- N-acetylglutamate synthase, mitochondrial
- Molecular Weight
- 58155.835 Da
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Transporter
- General Function
- Ankyrin binding
- Specific Function
- Functions as an electroneutral and bidirectional ammonium transporter. May regulate transepithelial ammonia secretion.
- Gene Name
- RHCG
- Uniprot ID
- Q9UBD6
- Uniprot Name
- Ammonium transporter Rh type C
- Molecular Weight
- 53178.56 Da
Drug created at November 17, 2015 18:59 / Updated at April 22, 2024 18:20